Cessation of GLP-1 RA therapy is associated with weight regain, and although current evidence does not provide conclusive findings regarding sarcopenia, the tendency to regain more fat than muscle mass, together with a potential decline in muscle quality, may pose a risk [98]
Substrate-like inhibitors often include proline mimetics that occupy the S 1 site
Increased Endurance: Helps preserve muscle glycogen by utilizing fatty acids for fuel, allowing for more sustained physical activity
Patients with inflammatory bowel disease considering semaglutide therapy should engage in comprehensive discussions with their healthcare team, ideally involving both their gastroenterologist and the physician prescribing the medication
Metabolic Disorders The recommended dose is 50 mg/kg given as a slow 2-3 minute bolus injection or by infusion
Is eloralintide FDA-approved